Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study

Yuan Hao Yang; Jen Kou Lin; Wei Shone Chen; Tzu Chen Lin; Shung Haur Yang; Jeng Kai Jiang; Yuan Tzu Lan; Chun Chi Lin; Chueh Chuan Yen; Cheng Hwai Tzeng; Hao Wei Teng

doi:10.1007/s00432-014-1741-0

Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study

Yuan Hao Yang, Jen Kou Lin, Wei Shone Chen, Tzu Chen Lin, Shung Haur Yang, Jeng Kai Jiang, Yuan Tzu Lan, Chun Chi Lin, Chueh Chuan Yen, Cheng Hwai Tzeng, Hao Wei Teng^*

^*Corresponding author for this work

Department of Surgery

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Methods: Between April 2005 and March 2012, patients (n = 158) diagnosed with metastatic colorectal cancer after at least four courses of first-line bevacizumab-based (n = 95) or cetuximab-based triplet (n = 63) were retrospectively analyzed. The KRAS genotypes were sequenced for all patients. The Kaplan–Meier method was used for survival analysis, and Cox proportional hazards models were used for univariate and multivariate analyses.

Results: Cetuximab-based triplet was associated with a higher objective response rate (66.0 vs. 47.2 %, p = 0.037) and a higher conversion rate to resectability (39.7 vs. 20.0 %, p = 0.007) compared to bevacizumab-based triplet. Compared with bevacizumab-based triplet, cetuximab-based triplet significantly increased progression-free survival in patients with measurable metastatic colorectal cancer who achieved objective tumor response (responders) (median 13.1 vs. 10.5 months, p = 0.023), but no significant increase was observed for overall survival. After adjustment for group differences in baseline characteristics and combined chemotherapy agents, cetuximab-based triplet remained an independent determinant of progression-free survival in responders as compared with bevacizumab-based triplet. KRAS mutation was not a prognostic factor in patients with metastatic colorectal cancer.

Conclusions: As compared with bevacizumab-based triplet, cetuximab-based triplet as the first-line treatment of metastatic colorectal cancer was associated with better progression-free survival in patients with measurable tumors who achieved objective tumor response to bio-chemotherapy.

Purpose: We aimed to compare the treatment efficacy of cetuximab versus bevacizumab in combination with either irinotecan-based or oxaliplatin-based regimens (targeted triplet) as the first-line treatment for patients with metastatic colorectal cancer.

Original language	English
Pages (from-to)	1927-1936
Number of pages	10
Journal	Journal of Cancer Research and Clinical Oncology
Volume	140
Issue number	11
DOIs	https://doi.org/10.1007/s00432-014-1741-0
State	Published - 14 Oct 2014

Keywords

Bio-chemotherapy
Conversion rate
KRAS
Metastasectomy
Targeted triplet

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00432-014-1741-0

Fingerprint

Dive into the research topics of 'Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study'. Together they form a unique fingerprint.

Cite this

Yang, Y. H., Lin, J. K., Chen, W. S., Lin, T. C., Yang, S. H., Jiang, J. K., Lan, Y. T., Lin, C. C., Yen, C. C., Tzeng, C. H., & Teng, H. W. (2014). Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study. Journal of Cancer Research and Clinical Oncology, 140(11), 1927-1936. https://doi.org/10.1007/s00432-014-1741-0

Yang, Yuan Hao ; Lin, Jen Kou ; Chen, Wei Shone et al. / Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer : Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study. In: Journal of Cancer Research and Clinical Oncology. 2014 ; Vol. 140, No. 11. pp. 1927-1936.

@article{7ea559098c6149e2addcf805b34285c6,

title = "Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study",

abstract = "Methods: Between April 2005 and March 2012, patients (n = 158) diagnosed with metastatic colorectal cancer after at least four courses of first-line bevacizumab-based (n = 95) or cetuximab-based triplet (n = 63) were retrospectively analyzed. The KRAS genotypes were sequenced for all patients. The Kaplan–Meier method was used for survival analysis, and Cox proportional hazards models were used for univariate and multivariate analyses.Results: Cetuximab-based triplet was associated with a higher objective response rate (66.0 vs. 47.2 %, p = 0.037) and a higher conversion rate to resectability (39.7 vs. 20.0 %, p = 0.007) compared to bevacizumab-based triplet. Compared with bevacizumab-based triplet, cetuximab-based triplet significantly increased progression-free survival in patients with measurable metastatic colorectal cancer who achieved objective tumor response (responders) (median 13.1 vs. 10.5 months, p = 0.023), but no significant increase was observed for overall survival. After adjustment for group differences in baseline characteristics and combined chemotherapy agents, cetuximab-based triplet remained an independent determinant of progression-free survival in responders as compared with bevacizumab-based triplet. KRAS mutation was not a prognostic factor in patients with metastatic colorectal cancer.Conclusions: As compared with bevacizumab-based triplet, cetuximab-based triplet as the first-line treatment of metastatic colorectal cancer was associated with better progression-free survival in patients with measurable tumors who achieved objective tumor response to bio-chemotherapy.Purpose: We aimed to compare the treatment efficacy of cetuximab versus bevacizumab in combination with either irinotecan-based or oxaliplatin-based regimens (targeted triplet) as the first-line treatment for patients with metastatic colorectal cancer.",

keywords = "Bio-chemotherapy, Conversion rate, KRAS, Metastasectomy, Targeted triplet",

author = "Yang, {Yuan Hao} and Lin, {Jen Kou} and Chen, {Wei Shone} and Lin, {Tzu Chen} and Yang, {Shung Haur} and Jiang, {Jeng Kai} and Lan, {Yuan Tzu} and Lin, {Chun Chi} and Yen, {Chueh Chuan} and Tzeng, {Cheng Hwai} and Teng, {Hao Wei}",

note = "Publisher Copyright: {\textcopyright} 2014, Springer-Verlag Berlin Heidelberg.",

year = "2014",

month = oct,

day = "14",

doi = "10.1007/s00432-014-1741-0",

language = "English",

volume = "140",

pages = "1927--1936",

journal = "Journal of Cancer Research and Clinical Oncology",

issn = "0171-5216",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "11",

}

Yang, YH, Lin, JK, Chen, WS, Lin, TC, Yang, SH, Jiang, JK, Lan, YT, Lin, CC, Yen, CC, Tzeng, CH & Teng, HW 2014, 'Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study', Journal of Cancer Research and Clinical Oncology, vol. 140, no. 11, pp. 1927-1936. https://doi.org/10.1007/s00432-014-1741-0

Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study. / Yang, Yuan Hao; Lin, Jen Kou; Chen, Wei Shone et al.
In: Journal of Cancer Research and Clinical Oncology, Vol. 140, No. 11, 14.10.2014, p. 1927-1936.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer

T2 - Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study

AU - Yang, Yuan Hao

AU - Lin, Jen Kou

AU - Chen, Wei Shone

AU - Lin, Tzu Chen

AU - Yang, Shung Haur

AU - Jiang, Jeng Kai

AU - Lan, Yuan Tzu

AU - Lin, Chun Chi

AU - Yen, Chueh Chuan

AU - Tzeng, Cheng Hwai

AU - Teng, Hao Wei

PY - 2014/10/14

Y1 - 2014/10/14

N2 - Methods: Between April 2005 and March 2012, patients (n = 158) diagnosed with metastatic colorectal cancer after at least four courses of first-line bevacizumab-based (n = 95) or cetuximab-based triplet (n = 63) were retrospectively analyzed. The KRAS genotypes were sequenced for all patients. The Kaplan–Meier method was used for survival analysis, and Cox proportional hazards models were used for univariate and multivariate analyses.Results: Cetuximab-based triplet was associated with a higher objective response rate (66.0 vs. 47.2 %, p = 0.037) and a higher conversion rate to resectability (39.7 vs. 20.0 %, p = 0.007) compared to bevacizumab-based triplet. Compared with bevacizumab-based triplet, cetuximab-based triplet significantly increased progression-free survival in patients with measurable metastatic colorectal cancer who achieved objective tumor response (responders) (median 13.1 vs. 10.5 months, p = 0.023), but no significant increase was observed for overall survival. After adjustment for group differences in baseline characteristics and combined chemotherapy agents, cetuximab-based triplet remained an independent determinant of progression-free survival in responders as compared with bevacizumab-based triplet. KRAS mutation was not a prognostic factor in patients with metastatic colorectal cancer.Conclusions: As compared with bevacizumab-based triplet, cetuximab-based triplet as the first-line treatment of metastatic colorectal cancer was associated with better progression-free survival in patients with measurable tumors who achieved objective tumor response to bio-chemotherapy.Purpose: We aimed to compare the treatment efficacy of cetuximab versus bevacizumab in combination with either irinotecan-based or oxaliplatin-based regimens (targeted triplet) as the first-line treatment for patients with metastatic colorectal cancer.

AB - Methods: Between April 2005 and March 2012, patients (n = 158) diagnosed with metastatic colorectal cancer after at least four courses of first-line bevacizumab-based (n = 95) or cetuximab-based triplet (n = 63) were retrospectively analyzed. The KRAS genotypes were sequenced for all patients. The Kaplan–Meier method was used for survival analysis, and Cox proportional hazards models were used for univariate and multivariate analyses.Results: Cetuximab-based triplet was associated with a higher objective response rate (66.0 vs. 47.2 %, p = 0.037) and a higher conversion rate to resectability (39.7 vs. 20.0 %, p = 0.007) compared to bevacizumab-based triplet. Compared with bevacizumab-based triplet, cetuximab-based triplet significantly increased progression-free survival in patients with measurable metastatic colorectal cancer who achieved objective tumor response (responders) (median 13.1 vs. 10.5 months, p = 0.023), but no significant increase was observed for overall survival. After adjustment for group differences in baseline characteristics and combined chemotherapy agents, cetuximab-based triplet remained an independent determinant of progression-free survival in responders as compared with bevacizumab-based triplet. KRAS mutation was not a prognostic factor in patients with metastatic colorectal cancer.Conclusions: As compared with bevacizumab-based triplet, cetuximab-based triplet as the first-line treatment of metastatic colorectal cancer was associated with better progression-free survival in patients with measurable tumors who achieved objective tumor response to bio-chemotherapy.Purpose: We aimed to compare the treatment efficacy of cetuximab versus bevacizumab in combination with either irinotecan-based or oxaliplatin-based regimens (targeted triplet) as the first-line treatment for patients with metastatic colorectal cancer.

KW - Bio-chemotherapy

KW - Conversion rate

KW - KRAS

KW - Metastasectomy

KW - Targeted triplet

UR - http://www.scopus.com/inward/record.url?scp=84919499233&partnerID=8YFLogxK

U2 - 10.1007/s00432-014-1741-0

DO - 10.1007/s00432-014-1741-0

M3 - Article

C2 - 24934725

AN - SCOPUS:84919499233

SN - 0171-5216

VL - 140

SP - 1927

EP - 1936

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

IS - 11

ER -

Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK et al. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study. Journal of Cancer Research and Clinical Oncology. 2014 Oct 14;140(11):1927-1936. doi: 10.1007/s00432-014-1741-0

Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this